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Summary
Background Guidelines for anal cancer recommend assessment of response at 6–12 weeks after starting treatment. 
Using data from the ACT II trial, we determined the optimum timepoint to assess clinical tumour response after 
chemoradiotherapy.
Methods The previously reported ACT II trial was a phase 3 randomised trial of patients of any age with newly 
diagnosed, histologically confirmed, squamous cell carcinoma of the anus without metastatic disease from 
59 centres in the UK. We randomly assigned patients (by minimisation) to receive either intravenous mitomycin 
(one dose of 12 mg/m² on day 1) or intravenous cisplatin (one dose of 60 mg/m² on days 1 and 29), with intravenous 
fluorouracil (one dose of 1000 mg/m² per day on days 1–4 and 29–32) and radiotherapy (50·4 Gy in 28 daily 
fractions); and also did a second randomisation after initial therapy to maintenance chemotherapy (fluorouracil and 
cisplatin) or no maintenance chemotherapy. The primary outcome was complete clinical response (the absence of 
primary and nodal tumour by clinical examination), in addition to overall survival and progression-free survival 
from time of randomisation. In this post-hoc analysis, we analysed complete clinical response at three timepoints: 
11 weeks from the start of chemoradiotherapy (assessment 1), 18 weeks from the start of chemoradiotherapy 
(assessment 2), and 26 weeks from the start of chemoradiotherapy (assessment 3) as well as the overall and 
progression-free survival estimates of patients with complete clinical response or without complete clinical 
response at each assessment. We analysed both the overall trial population and a subgroup of patients who had 
attended each of the three assessments by modified intention-to-treat. This study is registered at controlled-trials.
com, ISRCTN 26715889.
Findings We enrolled 940 patients from June 4, 2001, until Dec 16, 2008. Complete clinical response was achieved 
in 492 (52%) of 940 patients at assessment 1 (11 weeks), 665 (71%) of patients at assessment 2 (18 weeks), and 
730 (78%) of patients at assessment 3 (26 weeks). 691 patients attended all three assessments and in this subgroup, 
complete clinical response was reported in 441 (64%) patients at assessment 1, 556 (80%) at assessment 2, and 
590 (85%) at assessments 3.  151 (72%) of the 209 patients who had not had a complete clinical response at 
assessment 1 had a complete clinical response by assessment 3. In the overall trial population of 940 patients, 
5 year overall survival in patients who had a clinical response at assessments 1, 2, 3 was 83% (95% CI 79–86), 84% 
(81–87), and 87% (84–89), respectively and was 72% (66–78), 59% (49–67), and 46% (37–55) for patients who did 
not have a complete clinical response at assessments 1, 2, 3, respectively. In the subgroup of 691 patients, 5 year 
overall survival in patients who had a clinical response at assessment 1, 2, 3 was 85% (81–88), 86% (82–88), and 
87% (84–90), respectively, and was 75% (68–80), 61% (50–70), and 48% (36–58) for patients who did not have a 
complete clinical response at assessment 1, 2, 3, respectively. Similarly, progression-free survival in both the 
overall trial population and the subgroup was longer in patients who had a complete clinical response, compared 
with patients who did not have a complete clinical response, at all three assessments.
Interpretation Many patients who do not have a complete clinical response when assessed at 11 weeks after commencing 
chemoradiotherapy do in fact respond by 26 weeks, and the earlier assessment could lead to some patients having 
unnecessary surgery. Our data suggests that the optimum time for assessment of complete clinical response after 
chemoradiotherapy for patients with squamous cell carcinoma of the anus is 26 weeks from starting chemoradiotherapy. 
We suggest that guidelines should be revised to indicate that later assessment is acceptable.
Funding Cancer Research UK.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Lancet Oncol 2017; 18: 347–56
Published Online 
February 10, 2017 
http://dx.doi.org/10.1016/
S1470-2045(17)30071-2
This online publication has 
been corrected. The corrected 
version first appeared at 
thelancet.com/oncology on 
March 2, 2017
See Comment page 276
Mount Vernon Centre for 
Cancer Treatment, Northwood 
(R Glynne-Jones FRCR) 
University of Leeds, Leeds 
Cancer Centre, Leeds, UK 
(Prof D Sebag-Montefiore FRCR), 
Cancer Research UK and 
University College London 
Cancer Trials Centre, London, 
UK (H M Meadows MSc, 
R Begum BSc, S Beare PhD, 
Prof A Hackshaw MSc); Royal 
Marsden Hospital, London, UK 
(Prof D Cunningham MD); North 
Staffordshire Royal Infirmary, 
Stoke, UK (F Adab FRCR); 
Cheltenham General Hospital, 
Cheltenham, UK 
(K Benstead MD); Belfast City 
Hospital Cancer Centre, Belfast, 
UK (R J Harte MD); 
Northampton General 
Hospital, Northampton, UK 
(J Stewart FRCR); and Faculty of 
Natural and Environmental 
Sciences, University of 
Southampton, Southampton, 
UK (L Kadalayil PhD)
Correspondence to 
Dr Robert Glynne-Jones, 
Mount Vernon Hospital, 
Rickmansworth Road, 
Northwood, HA6 2RN, UK 
rob.glynnejones@nhs.net
Articles
348 www.thelancet.com/oncology   Vol 18   March 2017
Introduction
Standard treatment for anal cancer is chemoradiotherapy 
with concurrent fluorouracil and mitomycin.1–4 
Randomised phase 3 trials by the Radiotherapy Therapy 
Oncology Group (RTOG 98–11),5 the Action Clinique 
Coordonnées en Cancérologie Digestive (ACCORD 03) 
trial6 and the ACT II trial7 did not show benefit in terms of 
progression-free survival by increasing the radiotherapy 
boost dose,6 replacing mitomycin with cisplatin during 
chemoradiotherapy,5,6 or by giving maintenance chemo-
radio therapy after chemo radio therapy.7
Guidelines for anal cancer recommend assessment of 
response at 6–12 weeks after starting treatment but 
discordance exists regarding consideration of early 
biopsy.8–10 Several randomised trials and one population 
study used a single response assessment as an early 
endpoint (4–8 weeks after the completion of trial 
treatments) and showed that 10–60% of patients did not 
respond to chemoradiotherapy.1,2,3,11 On the basis of this 
evidence, salvage surgery can be done on patients who 
have residual tumour after completion of chemo-
radiotherapy.3,11
One of the primary endpoints of the ACT II trial was to 
assess whether cisplatin given concurrently with 
fluorouracil and radiotherapy produces a higher complete 
clinical response than mitomycin alone. A complete 
clinical response is defined as no evidence of residual 
tumour or nodal disease. Response was assessed at three 
timepoints up to 26 weeks from the start of 
chemoradiotherapy (figure 1). This post-hoc analysis of 
ACT II aimed to assess the difference in response at each 
of these timepoints and the association between having 
complete clinical response and progression-free or 
overall survival at each of these timepoints. This evidence 
can then be used indirectly to consider the best time for 
surgery. To the best of our knowledge, this assessment 
has not been prospectively investigated before.
Methods
Study design and participants
ACT II was a randomised phase 3 trial done in 
59 centres in the UK and designed to investigate 
whether replacing mitomycin with cisplatin in the 
chemoradiotherapy schedule improves the complete 
response rate, and whether maintenance chemotherapy 
(fluorouracil and cisplatin) after chemoradiotherapy 
increases progression-free survival. Patients were 
randomised to one of four groups to receive mitomycin 
(12 mg/m² on day 1) or cisplatin (60 mg/m² on days 1 
and 29) with fluorouracil (1000 mg/m² per day on 
days 1–4 and 29–32) and radiotherapy (50·4 Gy in 
28 day fractions); with or without two courses of 
maintenance chemotherapy (fluorouracil and cisplatin 
at weeks 11 and 14). The full trial methods and results 
have been reported previously.7
Participants
Patients were eligible if they had newly diagnosed, 
histologically confirmed squamous cell carcinoma 
basaloid or cloacogenic carcinoma of the anal canal or 
margin, without metastatic disease, and con-
sidered fit for trial treatment; a glomerular filtration rate 
of 50 mL/min or more; acceptable haematological 
para meters (haemoglobin >100 g per L, platelets 
>100 × 10⁹ per L, white blood cells >3 × 10⁹ per L); 
liver function tests within twice normal range; and 
adequate cardiac function. There were no age 
limits. Exclusion criteria were other major 
malignancies likely to compromise life expectancy or 
completion of trial therapy, comorbidity including 
HIV-positive status and cardiac diseases, previous 
complete local excision, and previous radiotherapy to 
the pelvis. All patients provided written informed 
consent and the trial was approved by UK research 
ethics committees.
Research in context
Evidence before this study
Standard treatment for anal cancer is chemoradiotherapy. 
Guidelines previously recommended assessment of tumour 
response and biopsy at 6–12 weeks after starting 
treatment on the basis of several randomised trials and a 
population study. On the basis of this evidence salvage 
surgery was recommended to be done on patients with 
residual tumour shortly after completing 
chemoradiotherapy. However, present guidelines offer 
discordant advice on how often and when biopsy should be 
done and offer uncertainty over the optimum timing of 
response.
Added value of this study
Our post-hoc analysis of our trial data shows that tumour 
assessment at 26 weeks from the start of chemoradiotherapy 
is most strongly associated with progression and mortality 
compared with any earlier assessment. Many patients who do 
not have a complete clinical response at 11 weeks from the 
start of chemoradiotherapy do respond by 26 weeks and are 
therefore considered slow to respond to treatment.
Implications of all the available evidence
Present guidelines on the best timing of tumour response for 
anal cancer should be strengthened and an assessment of 
response at 26 weeks should be used in future treatment trials, 
and should be explored as a surrogate endpoint for survival and 
progression.
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Randomisation
Randomisation was done by minimisation and stratified 
by site, T and N stage, sex, age, and renal function. 
Allocation was concealed by use of a computer program 
(in the trial co-ordinating centre) to generate the 
treatment allocation. Site staff would telephone the trial 
co-ordingating centre, and the assigned treatment was 
provided for the next patient. Patients, clinicians 
(including those assessing patients) and investigators 
analysing data were not masked to treatment allocation. 
Procedures
Briefly, all patients received 50·4 Gy delivered in 28 daily 
fractions over 38 days with fluorouracil on days 1–4 and 
29–32 by continuous intravenous infusion and either 
mitomycin as bolus on day 1 only or cisplatin by infusion 
on days 1 and 29.7 Patients randomly allocated to receive 
maintenance were given two additional courses of 
fluorouracil and cisplatin on days 71–74 and 92–95 after 
the start of chemoradiotherapy—ie, weeks 11 and 14. 
Before treatment, patients were staged according to the 
UICC 1990 staging system.12 Abdominopelvic CT scans 
and chest radiographs or thoracic CT scans were 
mandated, but not MRI or PET.
There were three primary tumour assessments (figure 1), 
made by the patient’s clinician (single clinical oncologist 
review). Assessment 1 (11 weeks from the start of 
chemoradiotherapy) was timed to allow any adverse events 
from radiotherapy to resolve and before patients randomly 
assigned to maintenance treatment started therapy. 
Assessment 2 was at 18 weeks from the start of chemo-
radiotherapy (4 weeks after completion of maintenance 
therapy for those receiving it) to assess the effect of 
maintenance therapy. Assessment 3 was at 26 weeks from 
the start of chemoradiotherapy in case of treatment delay 
and this timepoint has been used in other squamous cell 
cancers to allow for tumours that relapse or progress early.13 
Information about examination under anaesthetic was not 
collected during the trial and biopsies were not routinely 
done unless there was a high suspicion of residual disease 
because of anxieties from the radiation oncologist regarding 
healing in an irradiated area (according to UK practice). 
Patients who did not have a complete clinical response 
(those with partial response, stable disease, or progressive 
disease who did not have salvage surgery before week 26) at 
either assessment 1 or 2 could have subsequent assessments 
and delay interventions at the time (to determine slow 
responders). Patients diagnosed with progressive disease at 
assessment 1 or any other time before 26 weeks could still 
have assessment 2 or 3, but as their complete clinical 
response status could be influenced by any salvage 
treatment received they were excluded from all analyses.
Response was assessed according to Response 
Evaluation Criteria in Solid Tumors (version 1.0).14 Digital 
rectal examination was done at all three assessments, 
with mandatory abdominopelvic CT scan and chest 
radiograph or whole body CT scan at assessment 3 
(figure 1). Residual or recurrent disease was confirmed 
by biopsy before further therapy if results from other 
evaluations were ambiguous.
Patients were classified into two groups at each 
assessment: patients with a complete clinical response or 
patient without a complete clinical response (ie, patients 
with a partial response, stable disease, or disease 
progression). Patients who attended the assessments 
with insufficient response data were classified as 
“unknown” whereas those who either did not attend 
assessments or whose data were not reported were 
classified as “missing”. Where possible, the missing 
nodal status was extrapolated from the most recent 
previous and subsequent assess ments or follow-up 
information. In contrast to our previous publication of 
ACT II trial data,7 which defined complete response 
according to primary disease status only, in this report 
we included absence of nodal disease in the definition of 
complete clinical response to more accurately describe a 
group of patients with complete disappearance of 
tumour.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26Week
Chemoradiation
50·4 Gy in 25 fractions
over 38 days
Response
assessment 1
Digital rectal
examination
with or without
examination
under
anaesthestic
Response
assessment 2
Digital rectal
examination
with or without
examination
under
anaesthestic
Response
assessment 3
Digital rectal
examination
with or without
examination
under
anaesthestic
and CT
mandated*
Maintenance
chemotherapy
Figure 1: Treatment and assessment schedule in ACT II
*Patients referred for surgical salvage as appropriate.
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Outcomes
In the main trial evaluating chemoradiotherapy the 
primary endpoints were complete clinical response at 
26 weeks from the start of chemoradiotherapy, acute 
toxic effects for patients that received chemoradiotherapy 
and progression-free survival for patients that received 
maintenance chemotherapy. This post-hoc analysis 
investigated complete clinical response at all three 
assessments (11 weeks, 18 weeks, and 26 weeks from the 
start of chemoradiotherapy) as well as progression-free 
survival and overall survival measured from the time of 
randomisation. 
Statistical analysis
The association between tumour response and 
progression-free survival or overall survival at each 
timepoint was examined by Kaplan-Meier curves and Cox 
regression models. Crude and baseline adjusted hazard 
ratios (HRs) for achieving versus not achieving complete 
clinical response were calculated and adjusted for 
prognostic baseline factors and trial treatment. 
Progression-free survival events were defined as 
progressive disease, local recurrence (with or without 
metastases), metastases, or death from any cause. New 
tumours were not defined as progression-free survival 
events. Overall survival events included deaths from any 
cause. Time-to-event endpoints were measured from the 
date of randomisation, and patients without the event of 
interest were censored at date of last follow-up. Sensitivity 
analyses were done to check the effect of extrapolating 
nodal status when missing on the proportion of patients 
with a complete response.
To ensure that the analyses were not biased by the 
inclusion of patients who died before assessment 3, 
progression-free survival and overall survival were 
analysed both in all randomised patients using complete 
clinical response status where known, and those patients 
who attended clinic at all three timepoints and did not 
have salvage treatment before assessment 3.
Two sensitivity analyses of progression-free survival and 
overall survival was done using two extreme assumptions. 
The first was done on all ran domised patients, and where 
response status was unknown it was assumed to be 
complete clinical response, and the second was done on all 
ran domised patients, and where response status was 
unknown it was assumed to be not- complete clinical 
response. Analyses other than overall survival and 
progression-free survival were based on those patients 
who had tumour assessment data at all timepoints 
excluding those patients who had salvage treatment, to 
have a uniform dataset for these analyses, unaffected by 
missing tumour response data. All reported p values are 
two-sided, and analyses were done using Stata (version 12). 
We also examined the prognostic performance of complete 
clinical response status at each timepoint, using sensitivity 
and false-positive rates. This study is registered as at 
ISRCTN, number 26715889.
Role of the funding source
The funder had no role in study design, report writing, or 
collecting, analysing, or interpretation of the data. RG-J, 
DS-M, HMM, RB, SB, AH, and LK had full access to the 
data. All authors made the decision to submit the report 
for publication and gave final approval for submission.
Results
940 patients were enrolled from June 4, 2001, until 
Dec 16, 2008. The baseline characteristics of all 
individuals enrolled in the trial have been reported 
previously.7 Overall, the median age was 58 years, 
486 (52%) of 940 had a primary tumour of 5 cm or 
smaller (T1 or T2), 430 (46%) of 940 had a primary 
tumour larger than 5 cm or invasion to neighbouring 
organs (T3 or T4), 305 (32%) of 940 had positive lymph 
nodes, 787 (84%) of 940 had a tumour in the anal canal, 
and 132 (14%) of 940 had a tumour in the anal margin. 
Of the 940 patients, 249 were excluded for subgroup 
analysis: 241 patients did not attend all tumour 
assessments, or had results where it was not possible to 
determine response status, and eight patients had salvage 
treatment before the third assessment. The baseline 
characteristics of these 691 remaining patients who were 
analysed in this subgroup analysis were similar to both 
the entire trial population 940 patients (appendix p 1), 
and the 249 patients who were excluded (appendix p 2). 
The proportions of patients with primary tumour 
response data at all three assessments were similar in the 
two treatment groups (345 [73%] of 472 patients who 
received mitomycin vs 346 (74%) of 468 patients who 
received cisplatin; appendix p 3). Eight of 19 patients with 
confirmed early progressive disease at assessments 1 or 2 
had a potentially curative resection before week 26 and 
therefore had a complete clinical response at the third 
assessment (week 26). Excluding these patients in the 
analysis had a negligible effect on the results.
The median follow-up, censoring deaths, was 5·1 years 
(IQR 3·9–6·9) for all 940 patients and 5·2 years (4·0–6·8) 
for the 691 patients who attended all three assessments. 
There were 211 deaths and 292 progression-free survival 
events in the whole trial population. 23 of these deaths 
occurred before assessment 3. 12 patients died before 
assessment 1 (six from chemotherapy-related adverse 
events, two from anal cancer, three from reasons 
unrelated to cancer, and one from an unknown cause). 
Three died between assessments 1 and 2 (two by reasons 
unrelated to cancer and one from an unknown cause). 
Eight patients died between assessments 2 and 3 (six from 
anal cancer, one from radiotherapy, and one by suicide). 
There were 127 deaths and 182 progression-free survival 
events in the subgroup of 691 patients who had attended 
all three assessments.
Compliance to chemoradiotherapy in the subgroup pf 
691 patients who were assessable at all three timepoints 
was high and similar between the mitomycin and 
cisplatin groups (appendix p 4) and similar to that for all 
See Online for appendix
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940 trial patients.7 The median overall treatment time 
was 38 days (IQR 38–39 days) in both the mitomycin and 
cisplatin groups.
In our subgroup analysis of the 691 patients with 
response data at all three timepoints, the proportion of 
patients with complete clinical response increased 
over time: 441 (64%, 95% CI 61–67) of 691 patients 
had a complete clinical response at assessment 1, 
556 (81%, 78–88) at assessment 2, and 590 (85%, 
83–88) at assessment 3 (table 1, 2). 421 (95%) of 
441 patients who had a complete clinical response at 
assessment 1 maintained this complete clinical response 
at assessment 2 and 411 (93%) of 441 still had a complete 
clinical response at assessment 3 (table 3). The remaining 
30 (7%) of 441 patients either had a suspected relapse at 
assessment 2 or 3 (n=25) or they were missing data for 
nodal status (n=5). Complete clinical response was 
achieved in 492 (52%) of 940 patients at assessment 1 
(11 weeks), 665 (71%) of patients at assessment 2 
(18 weeks), and 730 (78%) of patients at assessment 3 
(26 weeks). However, 151 (72%) of 209 patients who were 
not in complete clinical response at assessment 1 
achieved complete clinical response by assessment 3, 
and 115 (76%) of 151 were alive and disease-free on last 
follow-up after treatment. Therefore, 115 (55%) of 
209 patients who did not have a complete clinical 
response at assessment 1 could be considered slow 
responders.
Of the overall trial population, 119 (13%) of 940 patients 
did not have a complete clinical response at assessment 3 
(table 3). Of these 119, two (2%) patients had 
defunctioning stomas for side-effects of radiotherapy, 
27 (23%) had salvage surgery (abdominoperineal excision 
of rectum or anorectal excision), and three had other 
types of surgery (all done after 26 weeks). Disease was 
pathologically confirmed before radical surgery.
The difference in the population of patients achieving a 
complete clinical response between patients in the 
cisplatin and mitomycin groups or between patients in 
the groups that received or did not receive maintenance 
was not significant at any assessment (table 1). There was 
no interaction between maintenance treatment and 
mitomycin or cisplatin (p=0·88 for both). The proportion 
of patients with a complete clinical response at 
assessment 3 (disregarding nodal status), was 311 (90%) 
of 345 for mitomycin and 313 (91%) of 346 for cisplatin 
(appendix p 3), similar to those among all 940 patients  as 
previously reported (391 [91%] of 432 patients treated 
with mitomycin and 386 [90%] of 431 patients treated 
with cisplatin).7 When nodal status was included at 
assessment 3 (26 weeks), the results were similar, with 
290 (84%) of 345 patients in the mitomycin group 
achieving a complete clinical response compared with 
294 (85%) of 346 patients in the cisplatin group 
(appendix p 3).
Regardless of when patients were assessed, clinical 
complete response was affected by patient’s tumour size 
and nodal stage (appendix p 5). Although the clinical 
complete response was significantly affected by tumour 
metastasis to neighbouring organs (compared with no 
tumour metastasis) at assessment 1 (p=0·0009), there was 
no longer a significant difference between patients with 
Overall (n=691) Mitomycin (n=345) Cisplatin (n=346) χ² No maintenance 
(n=347)*
Maintenance 
(n=305)
χ²
Assessment 1 441 (64%); (61–67) 231 (67%); (62–72) 210 (61%); (56–66) p=0·09 224 (65%); (60–70) 187 (61%); (56–67) p=0·39†
Assessment 2 556 (80%); (78–88) 273 (79%); (75–83) 283 (82%); (78–86) p=0·38 274 (79%); (75–83) 252 (83%); (78–87) p=0·24
Assessment 3 590 (85%); (83–88) 292 (85%); (81–88) 298 (86%); (82–90) p=0·58 294 (85%); (81–89) 264 (87%); (83–90) p=0·51
Data are shown as n (%); (95% CI), excluding eight patients who had salvage surgery. *39 of 691 patients did not get randomly assigned to the maintenance therapy (at physicians’ 
discretion), so they were not included in the maintenance analysis. The total number analysed for maintenance comparison is, therefore, 652 and not 691. †No difference in the 
proportion of patients with a complete response is expected between patients with and without maintenance therapy at assessment 1 because maintenance treatment would 
only start after this time. The p values shown were calculated with χ² tests.
Table 1: Complete clinical response at all three assessments in patients with primary tumour response data at all three assessments
Patients with complete 
clinical response
Patients without complete 
clinical response
Patients with unknown 
response data*
Assessment 1 441 209 41
Assessment 2 556 106 29
Assessment 3† 590 88 13
*Patients classified as “unknown” attended the assessment but had response data that were inconclusive. 
†23 patients died before assessment 3. Some patients did not attend for more than one assessment or had missing 
response data for more than one assessment so it is not possible to sum these numbers over all three timepoints.
Table 2: Distribution of patients and tumour response for patients who attended all three assessments 
(n=691) 
Patients with 
complete clinical 
response
Patients without 
complete clinical 
response
Patients with 
unknown response 
data*
Patients with 
missing data†
Assessment 1 492 235 82 131
Assessment 2 665 137 50 88
Assessment 3‡ 730 119 22 69
*Patients classified as “unknown” attended the assessment but had response data that were inconclusive. 
†Patients classified as “missing” included those for whom response data were not reported and patients who did not 
attend clinic for assessment. ‡23 patients died before assessment 3. Some patients did not attend for more than 
one assessment or had missing response data for more than one assessment so it is not possible to sum these numbers 
over all three timepoints.
Table 3: Distribution of patients and tumour response for all patients in the trial (n=940)
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and without metastasis to neighbouring organs at 
assessment 3 (p=0·08; appendix p 5). Clinical complete 
response was unaffected by age (patients aged 65 years 
and older compared with patients younger than 65 years). 
However, clinical complete response was affected by a 
patient’s sex at assessment 3, but not at assessment 1 
(appendix p 5). Overall survival of the overall trial 
population was analysed (with tumour response data, 
where available at any of the three assessments; figure 2). 
Table 4 shows the crude and adjusted HRs for overall 
survival. The 5 year overall survival for patients with 
complete clinical response and patients without a 
complete clinical response groups were: 83% (79–86) and 
72% (66–78) at assessment 1; 84% (81–87) and 59% (49–67) 
at assessment 2; and 87% (84–89) and 46% (37–55) at 
assessment 3. The overall survival for the subgroup of 
691 patients who had tumour assessments at all three 
timepoints was also assessed (appendix p 8) and was 
similar to that found in the overall trial population 
(table 4). The 5 year overall survival in this subgroup for 
patients with a complete clinical response and patients 
without a complete clinical response group was 85% (95% 
CI 81–88)and 75% (68–80) at assessment 1, 86% (82–88) 
and 61% (50–70) at assessment 2, and 87% (84–90) and 
48% (36–58) at assessment 3.
Progression-free survival for the overall trial population 
and the subgroup of patients with a response at all 
timepoints was also analysed (table 4, figure 3, appendix 
p 9). The 5 year progression-free survival in patients who 
had a complete clinical response compared with those 
who did not have a complete clinical response was 75% 
versus 63% at assessments 1, 75% versus 53% at 
assessment 2, and 80% versus 33% at assessment 3. 
Analysis of the subgroup of 691 patients who had data for 
all three timepoints yielded similar results (appendix 
p 9). There was no difference in progression-free survival 
events in patients who had a complete clinical response 
at assessment 1 (105 events in 441 patients) and those 
who had a complete clinical response only at assessment 3 
(nine events in 43 patients) (absolute difference 2·9 
[95% CI –9·9 to 15·7], p=0·67).
We did several analyses for overall survival and 
progression-free survival to check for consistency in the 
results because 241 of 940 patients had missing tumour 
assess ments at one or more timepoints (where the 
complete clinical response status was unavailable: 
unknown or missing) and eight patients who had 
available data were excluded because they had salvage 
treatment. Sensitivity analyses on the basis of imputing 
data for missing tumour response (with assumptions) 
and those who did not attend assessments (which 
includes those for which response data were not 
reported) provided similar results for both overall 
survival and progression-free survival as the main 
analysis (table 4, appendix pp 10–13); as well as for 
imputation for missing nodal status, assumed to be 
either positive or negative (appendix p 6). Furthermore, 
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Figure 2: Overall survival according to response at assessments 1, 2, and 3 among all 940 patients in whom 
response data were known
 cCR=complete clinical response. HR=hazard ratio.
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after excluding 23 deaths occurring before assessment 3 
(which would otherwise bias the group of patients with 
missing data), there was no difference in overall survival 
between patients who attended, patients who did not 
attend this assessment, or those with data not reported 
(table 3). At 1 year the overall survival was 96% (95% 
95–98) for 809 patients who attended assessment 1 
versus 91% (84–95) for patients who either did not attend 
or had data unreported at assessment 1. 1 year overall 
survival at assessment 2 was 97% (95–98) for the 
852 patients who attended compared with 90% (80–95) 
for 73 patients who did not attend or had data not 
reported, and 1 year overall survival at assessment 3 was 
98% (96–99) for the 871 patients who attended versus 
84% (70–92) for the 46 patients who did not attend or 
data not reported at assessment 3 (data not shown).
The sensitivity (ie the number of patients with a 
complete response who are alive relative to the total 
number of patient alive) of complete clinical response to 
predict overall survival was analysed at all three 
timepoints (appendix p 7). Sensitivity of complete clinical 
response to predict overall survival at 1 year was the 
highest at assessment 3 (88%) compared with at 
assessment 2 (85%) or assessment 1 (68%). The 
probability of a false-positive at 1 year was also the lowest 
at assessment 3 (20%) compared with assessment 2 
(32%) and assessment 1 (50%).
Discussion
Our results show that the proportion of those with a 
complete clinical response at 26 weeks (assessment 3) is 
more informative than either of the two earlier 
assessments, and that it is acceptable to monitor partial 
responders carefully up to the 26 week assessment. This 
extended period with careful monitoring has not been 
international practice to date, and there are patients who 
have salvage surgery because of residual tumour found 
shortly after completing chemoradiotherapy. Therefore it 
is important for patients and clinicians to establish the 
best time to assess tumour response, and we have done 
so with data from our clinical trial.
There was no evidence that maintenance therapy acted 
as a confounding factor for the association between 
complete clinical response status and overall survival and 
progression-free survival, as maintenance therapy did not 
influence whether a patient had complete clinical 
response. Moreover, maintenance treatment started only 
after assessment 1, there was no difference in the 
complete clinical response rates between patients with 
and without maintenance therapy (table 1), and there was 
no effect of maintenance therapy on either progression-
free survival or overall survival, as detailed in our original 
report on this trial.7 Since the median overall treatment 
time was the same in both the mitomycin and cisplatin 
groups (38 days [IQR 38–39 days]) the timing of 
assessment of complete clinical response was probably 
not confounded by variations in treatment duration. 
There was a substantial increase in the proportion of 
patients with a complete clinical response at 26 weeks 
(assessment 3) from the start of chemoradiotherapy 
compared with earlier assessments (table 1). These data 
are compatible with the RTOG-8704 trial results,1 which 
Overall survival Progression-free survival
Crude Adjusted* Crude Adjusted*
All 940 patients (using response data wherever available)
1 0·56 (0·40–0·77); p<0·0005 0·77 (0·50–1·18); p=0·22 0·59 (0·45–0·78); p<0·002 0·66 (0·46–0·95); p=0·02
2 0·30 (0·22–0·41); p<0·0001 0·40 (0·26–0·61); p<0·0001 0·37 (0·28–0·49); p<0·0001 0·43 (0·29–0·62); p<0·0001
3 0·17 (0·12–0·23); p<0·0001 0·22 (0·14–0·35); p<0·0001 0·16 (0·12–0·21); p<0·0001 0·15 (0·10–0·21); p<0·0001
691 patients with response data at all three timepoints†
1 0·55 (0·39–0·79); p=0·001 0·81 (0·51–1·29); p=0·38 0·61 (0·45–0·82); p=0·001 0·68 (0·46–0·99); p=0·05
2 0·30 (0·20–0·43); p<0·0001 0·44 (0·26–0·72); p=0·001 0·36 (0·26–0·50); p<0·0001 0·44 (0·29–0·66); p<0·0001
3 0·17 (0·12–0·24); p<0·0001 0·24 (0·14–0·40); p<0·0001 0·15 (0·11–0·21); p<0·0001 0·16 (0·10–0·24); p<0·0001
All 940 patients (missing response data assumed to be complete clinical response)
1 0·72 (0·54–0·96); p=0·028 0·98 (0·66–1·46); p=0·93 0·71 (0·55–0·92); p=0·01 0·79 (0·56–1·11); p=0·17
2 0·38 (0·28–0·52); p<0·0001 0·46 (0·30–0·70); p<0·0001 0·44 (0·33–0·58); p<0·001 0·46 (0·32–0·66); p<0·0001
3 0·25 (0·19–0·34); p<0·0001 0·31 (0·20–0·47); p<0·0001 0·21 (0·16–0·27); p<0·001 0·19 (0·13–0·27); p<0·0001
All 940 patients (missing response data assumed to be not complete clinical response)
1 0·51 (0·39–0·68); p<0·0001 0·68 (0·47–0·97); p=0·04 0·57 (0·45,0·72); p<0·0001 0·65 (0·48–0·89); p=0·01
2 0·31 (0·24–0·41); p<0·0001 0·40 (0·28–0·59); p<0·0001 0·39 (0·31,0·49); p<0·0001 0·49 (0·35–0·68); p<0·0001
3 0·16 (0·12–0·20); p<0·0001 0·19 (0·13–0·27); p<0·0001 0·16 (0·13–0·21); p<0·0001 0·17 (0·12–0·24); p<0·0001
Data are HR (95% cCI); p value. Complete clinical response is the complete disappearance of disease in the primary and nodes. *Adjusted for potential confounding factors: 
age, sex, site of primary, tumour differentiation, histology, baseline white blood cell count, baseline platelets, baseline haemoglobin, tumour size, nodal stage, and trial 
treatment. †Excluding eight patients who had salvage surgery.
Table 4: Association between overall survival or progression-free survival and tumour response at three different assessment timepoints
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mandated a biopsy after chemoradiotherapy at 4–6 weeks 
after completion of chemotherapy as part of the 
assessment and showed that the combination of 
mitomycin and fluorouracil with radiation produced a 
pathological complete response in 92% of patients at 
6 weeks after completing chemo radiotherapy.1 Patients 
with residual cancer shown in the biopsy after 
chemoradiotherapy were treated with a salvage regimen 
of additional pelvic radiotherapy (9 Gy), fluorouracil, and 
cisplatin (100 mg/m²). Of the 24 assessable patients who 
had salvage chemoradiotherapy, 12 (50%) were rendered 
disease-free. Our results imply that simply waiting longer 
might have achieved similar results. Our findings are also 
consistent with those previously described in a series of 
sequential chemoradiotherapy studies with mitomycin,15 
which showed that some patients with squamous cell 
carcinoma of the anus required 9–12 months to achieve a 
complete clinical response (defined as complete 
resolution of all clinical signs of the primary cancer for a 
duration of 2 months; if not, the tumour was scored as 
residual).
A limitation of our analysis is that the group which 
achieved a complete clinical response at assessment 3 
(week 26) does not truly represent all responders to 
chemoradiotherapy because it also includes patients who 
have had an early and sustained response and those who 
have a late response, but not patients who had a complete 
clinical response at assessment 1 but subsequently 
relapsed or did not have a complete clinical response by 
assessment 3.
Eventual outcomes (overall survival and progression-free 
survival) were independent of the timing that complete 
clinical response was achieved. These outcomes seem to 
be independent of whether complete clinical response was 
achieved at assessment 3 or at assessment 1. The HRs 
from both the overall survival and progression-free survival 
curves suggest that assessment 3 (26 weeks from the start 
of treatment) gives the most widely discriminating effect 
on survival outcomes, and suggests this is the optimum 
timepoint for assessment. Tumour assessment (including 
nodal status) at week 26 should therefore be explored as a 
surrogate endpoint for progression-free survival and 
overall survival in future trials.
These findings challenge guidelines8,9 for the post-
treatment follow-up of patients with anal cancer, which 
include serial digital rectal examination, with biopsy of 
clinically suspicious lesions recommended at weeks 4–6, 
6–8, and 8–12 after chemoradiotherapy completion, 
respectively. In our trial, not all 940 randomised patients 
had a known complete clinical response status at all three 
assessment timepoints. To address whether substantial 
bias could have arisen we made extreme assumptions 
about unknown status in two sensitivity analyses, and 
both produced the same conclusions irrespective of 
whether we considered the whole trial population or only 
those who attended all three assessments—ie, that the 
strongest association between complete clinical response 
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Figure 3: Progression-free survival according to response at assessments 1, 2, and 3 among all 940 patients in 
whom response data were known
cCR=complete clinical response. HR=hazard ratio.
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status and either overall survival or progression-free 
survival is at assessment 3.
Anal cancers can regress slowly after completion of 
chemo radiotherapy treatment. Accurate identification of 
response is a crucial component to optimise patient 
management. Clinical groups in the USA have 
recommended salvage surgery should only be considered 
after at least 12 weeks because complete resolution 
might take 3–6 months.1 The ideal method and timing of 
response evaluation and when maximum response 
occurs after chemoradiotherapy is unclear. Retrospective 
reports suggested initial early clinical response is an 
independent prognostic factor for survival.16–18 
Randomised studies have done clinical assessments of 
the tumour between 6 weeks and 12 weeks after 
completion of chemoradiotherapy.1–6
The mainstay of clinical evaluation has relied on digital 
rectal examination and careful examination of the 
inguinal regions. The limitations of this approach 
include the subjectivity of the clinical examination and 
the absence of treatment response information for any 
more deeply sited, non-palpable disease, including the 
pelvic lymph nodes. Also, radiotherapy-induced acute 
local effects can cause problems in our interpretation of 
response. Severe skin reactions, oedema, residual 
fibrosis, or scar tissue can be difficult to distinguish from 
persistent, active, or recurrent disease.19,20 The risk of 
radionecrosis should also be kept in mind when con-
sidering biopsy. A significant correlation has also 
been observed between high-grade acute toxicity in terms 
of skin reactions, cystitis, proctitis, or enteritis 
(National Cancer Institute Common Toxicity Criteria 
grade 3 or worse) during chemoradiotherapy and overall 
survival, loco regional control, and stoma-free survival.21
Imaging in terms of endoanal ultrasound or MRI has 
an established role in initial locoregional staging of the 
primary and pelvic lymph nodes,8,10 but their ability to 
assess response accurately is less welldefined.22 It can 
take 16–20 weeks to allow sufficient time for resolution 
of oedema to enable accurate classification of treatment 
response by ultrasound.23 MRI complements clinical 
assessment but can assign a worse stage prognosis to a 
patient, particularly lymph node status because enlarged 
lymph nodes can be recorded as node positive although 
many do not contain tumours. Metabolic and functional 
imaging techniques, such as diffusion-weighted MRI,24 
or PET with ¹⁸F-fluorodeoxyglucose,25–27 might offer an 
alternative option to assess response at an early timepoint 
without the potential morbidity of a biopsy, but large 
prospective studies are required.
The reported 5 year overall survival with salvage 
abdominoperineal resection for persistent or locally 
recurrent anal cancer was only 24–64%;28,29 hence, the 
rationale for proactive follow-up. For surgeons, there is 
always a tension between doing an early biopsy to define an 
early recurrence with limited locoregional disease, when 
surgical salvage is likely to be effective, and the risk of 
provoking necrosis from a biopsy after chemoradiotherapy. 
209 (30%) of 691 patients were not in complete clinical 
response 4 weeks after chemoradiotherapy (assessment 1); 
however, 115 remained disease-free at later follow-up, 
hence, early surgical salvage would not have been 
appropriate for these patients.
The RTOG-8704 trial mandated biopsy of the primary 
tumour at 4–6 weeks after a dose of 45 Gy to confirm 
complete pathological response in clinically residual 
disease,1 but routine biopsy is controversial in the 
monitoring of response to treatment, with some 
clinicians supporting random biopsies at a 3 month 
interval, while others support a biopsy only when there is 
a suspicious lesion.30
Our results suggest that early response assessments 
might not be reliable by failing to account for patients who 
are slow to respond to treatment. The data confirm that 
partial regression can be managed by close follow-up to 
confirm eventual complete regression. Others have 
recommended that patients deemed to be slow to respond 
(persistence of local disease with regression <50%) should 
be evaluated by at least two physicians at the end of 
radiotherapy, patients should be given an additional 
one or two courses of chemotherapy courses.31 However, 
our data previously showed no significant effect from an 
additional two cycles of maintenance chemotherapy 
(fluorouracil and cisplatin) after chemoradiotherapy 
(complete clinical response 82% vs 85% p=0·34).7
The ACT II chemoradiotherapy schedule achieved an 
excellent proportion of patients with an early complete 
clinical response, but our results show 151 (72%) of 
209 patients not in complete clinical response at 4 weeks 
after chemoradiotherapy achieved complete clinical 
response at 26 weeks. The consistency of the overall 
treatment time (median 38 days) makes the validity of 
our data for timing of complete clinical response 
assessment even stronger.
Although we would advise careful monitoring from 
completion of treatment to facilitate timely surgical 
salvage therapy for progressive disease, it seems safe to 
observe a resolving tumour up to 26 weeks after the start 
of chemoradiotherapy, and some patients could thus avoid 
unnecessary surgery. It might even be safe to extend 
evaluation beyond this timepoint, as some studies suggest 
a few patients might require more than 10 months for 
complete regression, but prospective data are required to 
confirm this timeline. We propose guidelines should be 
revised, and that the assessment of response at 26 weeks 
be used in future trials and explored as a surrogate 
endpoint for overall survival and progression-free survival.
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